COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
Abstract The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy withi...
Main Authors: | Mary J. Kasten, Brian D. Lahr, Anusha Parisapogu, Zachary A. Yetmar, John C. O’Horo, Robert Orenstein, Pablo Moreno Franco, Raymund R. Razonable, Paschalis Vergidis, Aditya S. Shah, Mark J. Enzler, David J. Inwards, Philippe R. Bauer |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-48145-x |
Similar Items
-
Diagnostic Methods and Risk Factors for Severe Disease and Mortality in Blastomycosis: A Retrospective Cohort Study
by: Timothy R. O’Dowd, et al.
Published: (2021-10-01) -
Effect of time and titer in convalescent plasma therapy for COVID-19
by: Paola de Candia, et al.
Published: (2021-08-01) -
Strangles, convalescent Streptococcus equi subspecies equi M antibody titers, and presence of complications
by: Katherine M. Delph, et al.
Published: (2019-01-01) -
COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
by: John F. McDyer, et al.
Published: (2023-05-01) -
Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
by: Christine Bäuerl, et al.
Published: (2023-06-01)